{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:34:07Z","timestamp":1778600047942,"version":"3.51.4"},"reference-count":13,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T00:00:00Z","timestamp":1405987200000},"content-version":"vor","delay-in-days":3489,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2005,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Toxic epidermal necrolysis (TEN) is a severe, immune\u2010mediated, mucocutaneous reaction resulting in extensive keratinocyte apoptosis. High\u2010dose human intravenous immunoglobulins (IVIG) have been proposed as an effective treatment for TEN. Retrospective data from 8 patients with TEN and 4 patients with Stevens\u2010Johnson syndrome\u2010toxic epidermal necrolysis (SJS\u2010TEN) overlap treated with high\u2010dose IVIG were analysed. The total dose of IVIG administered was 2 g\/kg body weight, with the exception of 2 patients who received a total dose of 1.5 g\/kg body weight. Their mean age was 49.9 \u00b1 18.8 years (range, 19 to 70 years). The mean time from the first sign of skin lesion or mucosal or epidermal detachment to commencement of IVIG was 8.7 \u00b1 5.5 days (range, 3 to 22 days). Of the 11 patients who survived, the mean time to objective response was 3.6 \u00b1 1.9 days (range, 2 to 8 days). The length of stay (LOS) in hospital was 20.4 \u00b1 8.0 days (range, 10 to 37 days). The survival rate was 91.6%. One patient developed permanent mucocutaneous sequelae following TEN. There were no adverse reactions to IVIG. We conclude that high\u2010dose IVIG may be a safe and effective therapy for Asian patients with TEN.<\/jats:p>","DOI":"10.1111\/j.1346-8138.2005.tb00704.x","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T08:55:05Z","timestamp":1406019305000},"page":"1-6","source":"Crossref","is-referenced-by-count":44,"title":["High\u2010Dose Intravenous Immunoglobulins in the Treatment of Toxic Epidermal Necrolysis: An Asian Series"],"prefix":"10.1111","volume":"32","author":[{"given":"Audrey W.","family":"Tan","sequence":"first","affiliation":[{"name":"National Skin Centre Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard Y.","family":"Thong","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Allergy and Immunology Tan Tock Seng Hospital Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard W.","family":"Yip","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Tan Tock Seng Hospital Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiok Hee","family":"Chng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Allergy and Immunology Tan Tock Seng Hospital Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"See Ket","family":"Ng","sequence":"additional","affiliation":[{"name":"National Skin Centre Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1996.tb06976.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1993.01680220104023"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1987.01660330071012"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5388.490"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64284-8"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.01622.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.120563"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62065-0"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.1.33"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)93395-P"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.1.26"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.1.39"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00130832-200308000-00006"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1346-8138.2005.tb00704.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1346-8138.2005.tb00704.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T23:18:58Z","timestamp":1700176738000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1346-8138.2005.tb00704.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["10.1111\/j.1346-8138.2005.tb00704.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1346-8138.2005.tb00704.x","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}